CSL Ltd shares slide as analysts weigh biotech prospects against Telix and HUB24

CSL Ltd (ASX:CSL) has seen its share price fall about 28.4% since the start of 2025, trading around $123.06 and trading at forward P/E multiples of roughly 15× for FY26‑27. The company, a global biotechnology firm with plasma‑derived therapies, vaccines and iron‑deficiency products, is praised for its dividend yield of about 3% and its established market position.

Analysts compare CSL with Telix Pharmaceuticals Ltd (ASX:TLX), which is developing radiopharmaceutical imaging and cancer‑treatment products. Telix trades at a much higher valuation—over 200× forecast earnings—reflecting greater uncertainty but also potential upside if its pipelines succeed. The commentary also highlights HUB24 Ltd (ASX:HUB), a wealth‑management software provider whose shares are near a 52‑week high after winning several industry awards.

Both pieces assess the relative risk‑return profiles of these Australian‑listed stocks for investors.